OBJECTIVE: To describe the prevalence, trends, and patterns in use of antidiabetic medications to treat hyperglycemia and insulin resistance before and during pregnancy in a large U.S. cohort of insured pregnant women. METHODS: Pregnancies resulting in live births were identified (N=437,950) from 2001 to 2007 among 372,543 females 12-50 years of age at delivery from 10 health maintenance organizations participating in the Medication Exposure in Pregnancy Risk Evaluation Program. Information for these descriptive analyses, including all antidiabetic medications dispensed during this period, was extracted from electronic health records and newborn birth certificates. RESULTS: A little more than 1% (1.21%) of deliveries were to women dispensed antidiabetic medication in the 120 days before pregnancy. Use of antidiabetic medications before pregnancy increased from 0.66% of deliveries in 2001 to 1.66% of deliveries in 2007 (P<.001) because of an increase in metformin use. Most women using metformin before pregnancy had a diagnosis code for polycystic ovaries or female infertility (67.2%), whereas only 13.6% had a diagnosis code for diabetes. The use of antidiabetic medications during the second or third trimester of pregnancy increased from 2.8% of deliveries in 2001 to 3.6% in 2007 (P<.001). Approximately two thirds (68%) of women using metformin before pregnancy did not use any antidiabetic medications during pregnancy. CONCLUSIONS: Antidiabetic medication use before and during pregnancy increased from 2001 to 2007, possibly because of increasing prevalence of gestational diabetes mellitus, type 1 and type 2 diabetes, and other conditions associated with insulin resistance. LEVEL OF EVIDENCE: III.
OBJECTIVE: To describe the prevalence, trends, and patterns in use of antidiabetic medications to treat hyperglycemia and insulin resistance before and during pregnancy in a large U.S. cohort of insured pregnant women. METHODS: Pregnancies resulting in live births were identified (N=437,950) from 2001 to 2007 among 372,543 females 12-50 years of age at delivery from 10 health maintenance organizations participating in the Medication Exposure in Pregnancy Risk Evaluation Program. Information for these descriptive analyses, including all antidiabetic medications dispensed during this period, was extracted from electronic health records and newborn birth certificates. RESULTS: A little more than 1% (1.21%) of deliveries were to women dispensed antidiabetic medication in the 120 days before pregnancy. Use of antidiabetic medications before pregnancy increased from 0.66% of deliveries in 2001 to 1.66% of deliveries in 2007 (P<.001) because of an increase in metformin use. Most women using metformin before pregnancy had a diagnosis code for polycystic ovaries or female infertility (67.2%), whereas only 13.6% had a diagnosis code for diabetes. The use of antidiabetic medications during the second or third trimester of pregnancy increased from 2.8% of deliveries in 2001 to 3.6% in 2007 (P<.001). Approximately two thirds (68%) of women using metformin before pregnancy did not use any antidiabetic medications during pregnancy. CONCLUSIONS:Antidiabetic medication use before and during pregnancy increased from 2001 to 2007, possibly because of increasing prevalence of gestational diabetes mellitus, type 1 and type 2 diabetes, and other conditions associated with insulin resistance. LEVEL OF EVIDENCE: III.
Authors: Angela D Liese; Ralph B D'Agostino; Richard F Hamman; Patrick D Kilgo; Jean M Lawrence; Lenna L Liu; Beth Loots; Barbara Linder; Santica Marcovina; Beatriz Rodriguez; Debra Standiford; Desmond E Williams Journal: Pediatrics Date: 2006-10 Impact factor: 7.124
Authors: Melissa A Parisi; Catherine Y Spong; Anne Zajicek; Alan E Guttmacher Journal: Am J Med Genet C Semin Med Genet Date: 2011-07-15 Impact factor: 3.908
Authors: Dana Dabelea; Ronny A Bell; Ralph B D'Agostino; Giuseppina Imperatore; Judith M Johansen; Barbara Linder; Lenna L Liu; Beth Loots; Santica Marcovina; Elizabeth J Mayer-Davis; David J Pettitt; Beth Waitzfelder Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Assiamira Ferrara; Henry S Kahn; Charles P Quesenberry; Candice Riley; Monique M Hedderson Journal: Obstet Gynecol Date: 2004-03 Impact factor: 7.661
Authors: Sandra S Albrecht; Elena V Kuklina; Pooja Bansil; Denise J Jamieson; Maura K Whiteman; Athena P Kourtis; Samuel F Posner; William M Callaghan Journal: Diabetes Care Date: 2010-01-12 Impact factor: 17.152
Authors: Joanne E Given; Maria Loane; Ester Garne; Marie-Claude Addor; Marian Bakker; Bénédicte Bertaut-Nativel; Miriam Gatt; Kari Klungsoyr; Nathalie Lelong; Margery Morgan; Amanda J Neville; Anna Pierini; Anke Rissmann; Helen Dolk Journal: BMJ Date: 2018-06-25
Authors: Rachel A Charlton; Kari Klungsøyr; Amanda J Neville; Sue Jordan; Anna Pierini; Lolkje T W de Jong-van den Berg; H Jens Bos; Aurora Puccini; Anders Engeland; Rosa Gini; Gareth Davies; Daniel Thayer; Anne V Hansen; Margery Morgan; Hao Wang; Anita McGrogan; Anne-Marie Nybo Andersen; Helen Dolk; Ester Garne Journal: PLoS One Date: 2016-05-18 Impact factor: 3.240
Authors: Carolyn E Cesta; Jacqueline M Cohen; Laura Pazzagli; Brian T Bateman; Gabriella Bröms; Kristjana Einarsdóttir; Kari Furu; Alys Havard; Anna Heino; Sonia Hernandez-Diaz; Krista F Huybrechts; Øystein Karlstad; Helle Kieler; Jiong Li; Maarit K Leinonen; Hanne L Gulseth; Duong Tran; Yongfu Yu; Helga Zoega; Ingvild Odsbu Journal: BMJ Open Diabetes Res Care Date: 2019-11-02